Zobrazeno 1 - 10
of 56
pro vyhledávání: '"Adeel S Zubair"'
Publikováno v:
Brain Circulation, Vol 10, Iss 1, Pp 60-66 (2024)
BACKGROUND AND OBJECTIVES: Amyotrophic lateral sclerosis (ALS) is a progressive motor neuron disease with no definitive treatment. Vitamin B12 is not a Food and Drug Administration-approved treatment in the United States, although it has been prescri
Externí odkaz:
https://doaj.org/article/5fab00b8578e4c9c9e0039e43a716643
Autor:
Adeel S. Zubair, Mark Landreneau, Jens Witsch, Robert K. Fulbright, Anita Huttner, Kevin N. Sheth, David Y. Hwang
Publikováno v:
Frontiers in Neurology, Vol 11 (2020)
Empiric anti-tuberculous therapy should not be delayed in patients with a strong clinical suspicion for TB. Because confirmatory TB testing may be difficult to obtain, early and empiric treatment, when there is concern for central nervous system TB,
Externí odkaz:
https://doaj.org/article/11b427bd117d4494916be890e81c573d
Transcriptomic signatures reveal immune dysregulation in human diabetic and idiopathic gastroparesis
Autor:
Madhusudan Grover, Simon J. Gibbons, Asha A. Nair, Cheryl E. Bernard, Adeel S. Zubair, Seth T. Eisenman, Laura A. Wilson, Laura Miriel, Pankaj J. Pasricha, Henry P. Parkman, Irene Sarosiek, Richard W. McCallum, Kenneth L. Koch, Thomas L. Abell, William J. Snape, Braden Kuo, Robert J. Shulman, Travis J. McKenzie, Todd A. Kellogg, Michael L. Kendrick, James Tonascia, Frank A. Hamilton, Gianrico Farrugia, the NIDDK Gastroparesis Clinical Research Consortium (GpCRC)
Publikováno v:
BMC Medical Genomics, Vol 11, Iss 1, Pp 1-10 (2018)
Abstract Background Cellular changes described in human gastroparesis have revealed a role for immune dysregulation, however, a mechanistic understanding of human gastroparesis and the signaling pathways involved are still unclear. Methods Diabetic g
Externí odkaz:
https://doaj.org/article/20e8bd3f92e147689f45774f66978f5d
Autor:
Sara Locke, Jane O’Bryan, Adeel S. Zubair, Melissa Rethana, Anne Spichler Moffarah, Peter J. Krause, Shelli F. Farhadian
Publikováno v:
Emerging Infectious Diseases. 29
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::35e219fc65033a0deec55637742a44e5
https://doi.org/10.3201/eid2906.221890
https://doi.org/10.3201/eid2906.221890
Publikováno v:
Frontiers in Neurology. 14
Idiopathic inflammatory myopathies (IIMs) are a group of acquired muscle diseases with muscle inflammation, weakness, and other extra-muscular manifestations. IIMs can significantly impact the quality of life, and management of IIMs often requires a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0a99b660e604238363df259bbfbad652
https://doi.org/10.3389/fneur.2023.1146015
https://doi.org/10.3389/fneur.2023.1146015
Autor:
Adeel S. Zubair, Kevin N. Sheth
Publikováno v:
Neurotherapeutics.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c50951353d62c5434d0ac9a025994c6d
https://doi.org/10.1007/s13311-023-01377-1
https://doi.org/10.1007/s13311-023-01377-1
Publikováno v:
Cureus.
Use of immune checkpoint inhibitors (ICI) is increasing in patients with oncologic disease. Three classes of checkpoint inhibitors exist: anti-PD1 (nivolumab, pembrolizumab), anti-CTLA4 (ipilimumab), and anti-PDL1 (atezolizumab, avelumab, durvalumab)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e260bc9c477b7e39e2b2e4a2a44e4ba
https://doi.org/10.7759/cureus.30638
https://doi.org/10.7759/cureus.30638
Publikováno v:
Cureus.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::30da6e781a87bfe0e0dc4b6ac26ce07f
https://doi.org/10.7759/cureus.30197
https://doi.org/10.7759/cureus.30197
Autor:
Ton Fang, Liqi Shu, Marwa Elnazeir, Adeel S. Zubair, Sami Al Kasab, Kateryna Antonenko, Mirjam R. Heldner, Shadi Yaghi, Nils Henninger
Publikováno v:
Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association. 31(12)
BACKGROUND AND PURPOSE There is a relative paucity of data regarding long-term outcomes and treatment-related complications in women of childbearing age with cerebral venous sinus thrombosis (CVST). We sought to determine whether outcomes differ in w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d0e7c6da03eba326ea5d0902520a556e
https://pubmed.ncbi.nlm.nih.gov/36332527
https://pubmed.ncbi.nlm.nih.gov/36332527
Autor:
Adeel S. Zubair, Kevin N. Sheth
Publikováno v:
Med (New York, N.Y.). 3(8)
The standard medical therapy for intravenous thrombolysis in patients with stroke presenting within 3 h is alteplase, a tissue plasminogen activator. Menon and colleagues assessed the non-inferiority, efficacy, and safety of tenecteplase, a modified
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6dfc85c9c8f2bb80a860abaf176bf4f
https://pubmed.ncbi.nlm.nih.gov/35963230
https://pubmed.ncbi.nlm.nih.gov/35963230